| Biomarker ID | 496 |
| PMID | 19894759 |
| Year | 2009 |
| Biomarker | e-FABP5 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in LNM PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-PPAR signaling pathway, Interleukin-1 regulation of extracellular matrix |
| Experiment | Lymph Node Metastatic Prostate Cancer Vs Localised PCA |
| Type of Biomarker | Prognostic |
| Cohort | Serum samples were obtained from 70 additional patients at the initial diagnosis, including 20 cases of localized PCa, 20 cases of LNM PCa and 30 cases of BPH |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | FABP5 |